Leong Justin

RMD CPO Justin Leong sells 6,160 shares ($1.5M) at $243.09; holds 21,718 post-sale as stock trades -2.5% from 52-week high

Justin Leong, Chief Product Officer of ResMed, sold 6,160 shares for $1,497,415.92 on 2024-11-22 at $243.09 per share, reducing his holdings by -22.1% to 21,718 shares. The sale occurred at a price near recent lows within the 52-week range ($152.52–$256.07), with the stock currently trading at $249.56 or -2.5% from its 52-week peak. His prior open-market sale of ResMed shares on 2024-08-05 produced a 90-day return of +12.5%, meaning the stock rose after his previous sale—a poorly-timed outcome. No meaningful directional signal is apparent from a single insider's discretionary sale; the magnitude of the position reduction and proximity to 52-week highs warrants routine monitoring of ResMed's forward guidance and product-line performance.

Leong Justin (Pres. Asia Latin America, RMD) sells 48,000 shares at $217.07; holdings drop 71.9% to 18,741 shares

Leong Justin, President of Asia Latin America, executed a substantial sale of 48,000 shares on 2024-08-05 at $217.07, reducing his post-transaction holdings to 18,741 shares—a 71.9% reduction from his prior 66,741 shares. The sale occurred at a price within the 52-week range ($134.65–$223.64) and only 2.2% below the 52-week high of $223.64. The company's recent fundamentals show strong performance with net income of $300,492,000.00 on revenue of $1,196,980,000.00 and annual revenue growth of 18.0%, suggesting solid operational health at the time of the transaction. The magnitude of the position reduction—from near 67K to under 19K shares—represents a significant realignment of this executive's personal exposure to RMD.